Article info
PDFResearch Article
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry
- ↵a Mayer.Fishman{at}moffitt.org
- ↵b jpd4401{at}aol.com
- ↵c jclark{at}lumc.edu
- ↵d ajjai{at}med.umich.edu
- ↵e gpmile{at}cox.net
- ↵f brendan.curti{at}providence.org
- ↵g Neeraj.Agarwal{at}hci.utah.edu
- ↵h rhauke{at}nebraskacancer.com
- ↵i Kmmah5{at}bidmc.harvard.edu
- ↵j Helen.H.Moon{at}kp.org
- ↵k jtreisman{at}gmail.com
- ↵l stykodi{at}fredhutch.org
- ↵m gdaniels{at}ucsd.edu
- ↵n michael.morse{at}duke.edu
- ↵o michaelkwongmd{at}gmail.com
- ↵p howardkaufman6{at}gmail.com
- ↵q nancy.gregory{at}prometheuslabs.com
- ↵r dmcdermo{at}bidmc.harvard.edu
Citation
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry
Publication history
- Received December 5, 2018
- Accepted March 14, 2019
- First published March 27, 2019.
Online issue publication
January 08, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.